eRAPID electronic patient self-reporting of adverse-events: patient information and advice: a pilot study protocol in pelvic radiotherapy.
dc.contributor.author | Holch, P | |
dc.contributor.author | Pini, S | |
dc.contributor.author | Henry, A | |
dc.contributor.author | Davidson, Susan E | |
dc.contributor.author | Routledge, Jacqueline A | |
dc.contributor.author | Brown, J | |
dc.contributor.author | Absolom, K | |
dc.contributor.author | Gilbert, A | |
dc.contributor.author | Franks, K | |
dc.contributor.author | Hulme, C | |
dc.contributor.author | Morris, C | |
dc.contributor.author | Velikova, G | |
dc.date.accessioned | 2018-09-15T19:30:04Z | |
dc.date.available | 2018-09-15T19:30:04Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | eRAPID electronic patient self-reporting of adverse-events: patient information and advice: a pilot study protocol in pelvic radiotherapy. 2018, 4: 110 Pilot Feasibility Stud | en |
dc.identifier.issn | 2055-5784 | |
dc.identifier.pmid | 29992040 | |
dc.identifier.doi | 10.1186/s40814-018-0304-6 | |
dc.identifier.uri | http://hdl.handle.net/10541/621243 | |
dc.description.abstract | An estimated 17,000 patients are treated annually in the UK with radical radiotherapy (RT) for pelvic cancer. New treatment approaches in RT have increased survivorship and changed the subjective toxicity profile for patients who experience acute and long-term pelvic-related adverse events (AE). Multi-disciplinary follow-up creates difficulty for monitoring and responding to these events during treatment and beyond. Originally developed for use in systemic oncology therapy eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is an online system for patients to report AEs from home. eRAPID enables patient data to be integrated into the electronic patient records for use in clinical practice, provides patient management advice for mild and moderate AE and advice to contact the hospital for severe AE. The system has now been developed for pelvic RT patients, and we aim to test the intervention in a pilot study with staff and patients to inform a future randomised controlled trial (RCT). | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Pilot and feasibility studies | en |
dc.title | eRAPID electronic patient self-reporting of adverse-events: patient information and advice: a pilot study protocol in pelvic radiotherapy. | en |
dc.type | Article | en |
dc.contributor.department | Department of Psychology, School of Social Sciences, Leeds Beckett University, Calverley Building, Room CL 815 City Campus, Leeds, LS1 9HE UK | en |
dc.identifier.journal | Pilot and Feasibility Studies | en |
refterms.dateFOA | 2018-12-17T15:37:44Z | |
html.description.abstract | An estimated 17,000 patients are treated annually in the UK with radical radiotherapy (RT) for pelvic cancer. New treatment approaches in RT have increased survivorship and changed the subjective toxicity profile for patients who experience acute and long-term pelvic-related adverse events (AE). Multi-disciplinary follow-up creates difficulty for monitoring and responding to these events during treatment and beyond. Originally developed for use in systemic oncology therapy eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice) is an online system for patients to report AEs from home. eRAPID enables patient data to be integrated into the electronic patient records for use in clinical practice, provides patient management advice for mild and moderate AE and advice to contact the hospital for severe AE. The system has now been developed for pelvic RT patients, and we aim to test the intervention in a pilot study with staff and patients to inform a future randomised controlled trial (RCT). |